DOCSLIB.ORG

Abcl 73 Acquired Immunodeficiency Syndrome (AIDS) 73 Acute Tubular

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Abcl 73 Acquired Immunodeficiency Syndrome (AIDS) 73 Acute Tubular Index ABCl 73 apoptotic DNA ladder 7 acquired immunodeficiency syndrome (AIDS) arachidonic acid (AA) 19 73 aurin tricarboxylic acid 9 acute tubular necrosis 227,229 autoimmune disease 13 aggrecanase 166 autoimmune hemolytic amenia 47 anemia of chronic diseases (ACD) 92 autoreactive T cell 10 angiogenesis 232 anoikis 131 B cell, regulation of 47 anti-apoptotic drug 173 B1 integrin 124 antibody dependent cellular cytotoxicity B1 integrin (CD29) receptor 124 (ADCC) 135 BAD 12 anti-phospholipid autoantibody 73 basement membrane 121 anti-SSNRo antibody 137 Bax 134,170,229 Apaf-l 9 bcl-2 11-13, 128, 129, 134, 138, 154, 170, aplastic anemia 93 216,228-231,233 apoptosis 7, 19,213,227,228 bcl-2 family members, phosphorylation status of apoptosis, cell survival protein p35 blocked 12 174 bcl-x 128, 129 a poptosis, characteristics of bcl-XL 12 apoptosis, constitutive 57 bone morphogenetic protein (BMP) 173 apoptosis, defense against 126 bystander lysis 42 apoptosis, Fas dependent 41 apoptosis, inadequate 151 Caenorhabditis elegans 9 apoptosis, in physiology and disease 3 calcipotriene 222 apoptosis, reduced 153 calcium-dependent nuclease 9 apoptosis, regulation of 2 camptothecin 167 apoptosis, TNF dependent 44 cancer 13 apoptosis, ultraviolet radiation (UVR)-induced cartilage 163 126 cartilage degradation 164 apoptosis of erythroid progenitors 92 caspase 9, 11, 13,44,227-230 apoptotic body 7, 111 caspase-3 9, 166 239 Index caspase-10 12 death receptor 5 104 caspase-activated DNase (CAD) 70 defense against apoptosis 126 CDllb -/- mouse 66 desquamin 132 CD14 73 dexamethasone 8, 9 CD27 156 diadenosine polyphosphate 72 CD36 63 DNA degradation, internucleosomal 10 CD40 48 DNA fragmentation factor (DFF) 9 CD40L 47 DNA laddering 228 CD44 74 CD45 11 endochondral bone formation 164 CD69 69 endochondral ossification 107 CD70 156 eosinophil 56,57, 91 ced-3 9 eosinophil deletion by apoptosis 59 cell proliferation 19 eosinophil development 91 CEM human leukemia cell 8 eosinophil granulocyte 56 c-fos 154 epidermal differentiation 130 chemokine 61 epidermal growth factor receptor (EGFR) 123, chondrocyte apoptosis 164 216 chronic granulomatous disease 66 epidermis 121,218 clusterin 230 epithelial cell 227 c-myc 8, 154, 228, 229 Erythema multiforme 137 colony forming units-erythroid (CFU-E) 92 erythropoietin (EPO) 86, 92 colony forming units-megakaryocyte (CFU-MK) extracellular matrix (ECM) 72, 131 93 congenital CD18 deficiency 66 FADD 10 cpk mouse 228 Fas 8,9,48,68,129,166,220,231 CTLA4 46 Fas (CD95, Apo-1) 10 cyclic AMP 74 Fas activation 133 cycloheximide 128, 132 Fas antigen 104 cyclosporin A 220 Fas ligand 68, 220 cytochrome C 9, 12 Fas ligation 68 cytokine 87, 135 Fas molecule ligand FasL 152 cytokine network 85, 89 Fas receptor 227 cytoplasmic acidification 70 Fas/Fas ligand 40, 91 cytoplasmic tyrosine kinase 71 FasITNF family 46 cytotoxicity, immunologic 135 FasL 47,136 FasL gene transfer 157 Darier's disease 138 FGF signaling pathway 124 dATP 9 FGFR3 129 death domain 10, 12 fibroblast-like synoviocyte (FLS) 149 death program, constitutive 69 a4~1 fibronectin receptor 72 death receptor 4 104 FLICE 10 240 Index FLIP (Casper) 12 hematopoietic factor, inhibitory 86 Fos-LacZ transgenic mouse 171 hematopoietic growth factor 85 hematopoietic trophic factor 87 gelatinase-B (MMP-9) 166 hemolytic anemia 46 gene expression 8 host-reactive immune cell 7 glomerulonephritis 230, 231 human immunodeficiency virus (HIV) 227,232, glomerulosclerosis 227,230,232,233 233 glucocorticoid 8, 12, 74, 222 hyaluronan 103 glucocorticoid receptor (GR) 8, 11 hyaluronic acid (HA) 103 glucocorticoid steroid 58 hypertrophic chondrocyte 164 graft versus host disease (GVHD) 136 hypertrophic phenotype 165 granule exocytosis model 40 granulocyte 53 IgA nephropathy 231 granulocyte colony-stimulating factor (G-CSF) IgG Fc receptor (FcyR)-mediated apoptotic 86,92 pathway of eosinophil 91 granulocyte colony-stimulating factor (G-CSF), immune activation 135 maintaining viability 90 inflammation 53 granulocyte colony-stimulating factor (G-CSF), inflammation, apoptosis in resolution 58 supporting the growth of colony forming inflammatory arthritis 55 units-megakaryocyte (CFU-MK) 93 inflammatory bowel disease 47 granulocyte death 53 inflammatory cytokine 87,90 granulocyte lifespan 53 inflammatory disease 13 granulocyte-macrophage colony-stimulating inositol 1,4,5-triphosphate receptor (IP3Rl) 9 factor (GM-CSF) 86,91 insulin-like growth factor binding protein-3 217 granulocyte-macrophage colony-stimulating integrin 217 factor (GM-CSF), autocrine production of ~2 integrin 66 91 interferon aJ~ (IFNaJ~), enhancing apoptosis 90 granulocyte-macrophage colony-stimulating interferon y (IFNy) 91 factor (GM-CSF), inhibiting apoptosis 90 interferon y (IFNy), enhancing apoptosis 90 granulocyte-macrophage colony-stimulating interferon y (IFNy), inhibitory activity on factor (GM-CSF), maintaining viability 90 CFU-E 92 granulocyte-macrophage colony stimulating interferon y (IFNy), inhibitory effects of 90 factor (GM-CSF), supporting the growth of interferon regulatory factor (IRF-1) 11 colony forming units-megakaryocyte (CFU­ interleukin-1 (IL-1) 91,92, 166 MK) 93 interleukin-l (IL-1), inhibitory activity on granzyme B 136, 152, 153 CFU-E 92 growth plate 105 interleukin-l (IL-l), inhibitory effects of 90 growth plate, developing 165 interleukin-l (IL-1), maintaining viability 90 interleukin-2 (IL-2) 11,47 hair follicle 122, 138 interleukin-2 (IL-2), inhibitory effects of 90 hematopoietic cell, expansion 85 interleukin-3 (IL-3) 86, 91, 92 hematopoietic cell, turnover 85 interleukin-3 (IL-3), inhibiting apoptosis 90 241 Index interleukin-4 (IL-4) 11, 12 Iymphoproliferation (lpr) mouse 10 interleukin-4 (IL-4), inhibiting apoptosis 90 Iymphoproliferative syndrome 47 interleukin-4 (IL-4), inhibitory effects of 90 interleukin-5 (IL-5) 86, 91 macrophage 149 interleukin-5 (IL-5), autocrine production 91 macrophage, human monocyte derived 55 interleukin-5 (IL-5), inhibiting apoptosis 90 macrophage, inflammatory 55 interleukin-6 (IL-6) 92,93,218 macrophage, production of 91 interleukin-6 (IL-6), maintaining viability 90 macrophage, responses to uptake of apoptotic interleukin-7 (IL-7) 11,219 granulocytes 61 interleukin-9 (IL-9) 12 macrophage colony-stimulating factor (M-CSF) interleukin-10 (IL-10) 69 86 interleukin-15 (IL-15) 154 matrix metalloproteinase (MMP) 166 intracellular calcium 8, 9, 11 matrix metalloproteinase (MMP) inhibitors to involucrin 132 block matrix degradation 173 ionizing radiation 9 matrix metalloproteinase (MMP) stromelysin-1 ischemia 227,230 171 mcl-1 128 jck mouse 229 melanocyte 121, 135 joint fluid 55 membrane attack complex (MAC) 135 Jun NHz terminal kinase (JNK) 45 mesangial cell 227,231 Jurkat cell 9 MIP-1a 90 mitochondrial membrane potential 7 keratinocyte 213 mitochondrium 106, 107 keratinocyte apoptosis 122 mitosis 11 keratinocyte differentiation 123 multiple sclerosis (MS) 42 kidney 227, 229, 232, 233 myeloperoxidase (MPO) 59 kidney development 227 myelopoiesis 90 Kit ligand (KL) 86, 92 Kit ligand (KL), maintaining viability 90 necrosis 7 nerve growth factor (NGF) 129 laminin B1 9 neutrophil 57, 222 Lagerhans cell 122, 135 neutrophil, caspase-3 70 late apoptotic cell 64 neutrophil, circulation half life 54 late-stage (mature) anti-apoptotic therapy 174 neutrophil apoptosis, loss of injurious properties lectin 73 58 Lichen planus 136 neutrophil apoptosis, shedding of cell surface light therapy 218 receptors 59 lupus nephritis 231 nitric oxide (NO) 9,68, 105, 152, 166 lymphocyte 218 non-steroidal anti-inflammatory drug (NSAID) lymphocyte, activity 7 173 lymphocyte, development 7 nuclease 13 lymphocyte, selection 7 nuclear factor KB (NFKB) 45 242 Index oncosuppressor gene 154 PThrP 170 osteoarthritis (OA) 110, 163 pyrophosphate (PPi) 108 overlapping function 87 ras 154 oxidative stress 66 rat thymocyte 8 oxygen radical 152 reactive oxygen species 66, 135 redundancy 87 p53 133,134,154,217,228,229 Reiter's cell 55 p53 mutation 154 renal disease 227 p56lck 11 retinoid 220 p57kip2 170 retro-retinoid (RR) 221 pathogenesis 149 rheumatoid arthritis (RA) 46, 110, 149 pcy mouse 228 RU486 8 perforin 135 perforinfgranzyme mechanism of apoptosis S49 mouse lymphoma cell 8 40 scavenger receptor 73 phagocyte, semi-professional, fibroblast 64 self-ractive specificity 46 phagocyte, semi-professional, mesangial cell serine protease 135 64 serine/threonine protein phosphatase inhibitor phagocytosis of apoptotic neutrophils 61 okadaic acid 167 phosphatidyl serine 64 severe combined immunodeficiency (SCID) 11 phosphatidyl serine residue 7 spinous layer 121 phospholipase C (PLC) 11 sterol-regulatory element-binding protein photosensitive lupus 137 (SREBP) 9 pityriasis ruba pilaris 138 Stevens-Johnson syndrome 137 PKC inhibitor 12 stratum corneum 121 platelet 72 stromelysin-1 (MMP-3) 166 platelet production 93 subacute cutaneous lupus erythematosus (SCLE) polycystic kidney disease 227,228 137 poly ADP-ribose polymerase (PARP) 9 sunburn cell 126, 133 primary antiphospholipid antibody syndrome survival factor, granulocyte colony stimulating (PAPS) 74 factor (G-CSF) 57 proerythroblast 92 survival factor, granulocyte-macrophage colony pro-inflammatory cytokine 61 stimulating factor (GM-CSF) 57 protease cascade 9 survival factor, interleukin-5 (IL-5) 57 protein kinase C inhibitor staurosporine synovitis 153 167 synovium 149 protein synthesis inhibition 132 systemic lupus erythematosus (SLE) 46 proto-oncogene 154 systemic vasculitis 58 PS receptor 64 psoraten plus UVA (PUVA) 218 T cell 156,219 psoriasis 138,213
Load more

Recommended publications
  • The Role of Immunogenic Cell Death
    University of Southern Denmark Current approaches for combination therapy of cancer The role of immunogenic cell death Asadzadeh, Zahra; Safarzadeh, Elham; Safaei, Sahar; Baradaran, Ali; Mohammadi, Ali; Hajiasgharzadeh, Khalil; Derakhshani, Afshin; Argentiero, Antonella; Silvestris, Nicola; Baradaran, Behzad Published in: Cancers DOI: 10.3390/cancers12041047 Publication date: 2020 Document version: Final published version Document license: CC BY Citation for pulished version (APA): Asadzadeh, Z., Safarzadeh, E., Safaei, S., Baradaran, A., Mohammadi, A., Hajiasgharzadeh, K., Derakhshani, A., Argentiero, A., Silvestris, N., & Baradaran, B. (2020). Current approaches for combination therapy of cancer: The role of immunogenic cell death. Cancers , 12(4), [1047]. https://doi.org/10.3390/cancers12041047 Go to publication entry in University of Southern Denmark's Research Portal Terms of use This work is brought to you by the University of Southern Denmark. Unless otherwise specified it has been shared according to the terms for self-archiving. If no other license is stated, these terms apply: • You may download this work for personal use only. • You may not further distribute the material or use it for any profit-making activity or commercial gain • You may freely distribute the URL identifying this open access version If you believe that this document breaches copyright please contact us providing details and we will investigate your claim. Please direct all enquiries to [email protected] Download date: 04. Oct. 2021 cancers Review Current
    [Show full text]
  • Activating Death Receptor DR5 As a Therapeutic Strategy for Rhabdomyosarcoma
    International Scholarly Research Network ISRN Oncology Volume 2012, Article ID 395952, 10 pages doi:10.5402/2012/395952 Review Article Activating Death Receptor DR5 as a Therapeutic Strategy for Rhabdomyosarcoma Zhigang Kang,1, 2 Shi-Yong Sun,3 and Liang Cao1 1 Genetics Branch, Center for Cancer Research, National Cancer Institute, Bethesda, MD 20892, USA 2 Laboratory of Proteomics and Analytical Technologies, SAIC-Frederick, Inc., NCI Frederick, Frederick, MD 21702, USA 3 Department of Hematology and Medical Oncology, Winship Cancer Institute, Emory University School of Medicine, Atlanta, GA 30322, USA Correspondence should be addressed to Liang Cao, [email protected] Received 4 January 2012; Accepted 24 January 2012 Academic Editors: E. Boven and S. Mandruzzato Copyright © 2012 Zhigang Kang et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. Rhabdomyosarcoma (RMS) is the most common soft tissue sarcoma in children. It is believed to arise from skeletal muscle progenitors, preserving the expression of genes critical for embryonic myogenic development such as MYOD1 and myogenin. RMS is classified as embryonal, which is more common in younger children, or alveolar, which is more prevalent in elder children and adults. Despite aggressive management including surgery, radiation, and chemotherapy, the outcome for children with metastatic RMS is dismal, and the prognosis has remained unchanged for decades. Apoptosis is a highly regulated process critical for embryonic development and tissue and organ homeostasis. Like other types of cancers, RMS develops by evading intrinsic apoptosis via mutations in the p53 tumor suppressor gene.
    [Show full text]
  • Potential Tumor-Promoting Effects of Ectopic Cd137 Expression on Hodgkin Lymphoma
    POTENTIAL TUMOR-PROMOTING EFFECTS OF ECTOPIC CD137 EXPRESSION ON HODGKIN LYMPHOMA HO WENG TONG (B. Sci (Biomedical Sci.), UPM, Malaysia) A THESIS SUBMITTED FOR THE DEGREE OF DOCTOR OF PHILOSOPHY DEPARTMENT OF PHYSIOLOGY NATIONAL UNIVERSITY OF SINGAPORE 2013 i Acknowledgement I would like to take this opportunity to address my appreciation to my thesis supervisor, Associate Professor Herbert Schwarz, who had provided me with exceptional guidance and advice throughout my candidature. Besides that, he also gave me a lot of supports and this study would not be possible without his truly contributions. I would also like to thank Dr. Shao Zhe, Dr Jiang Dongsheng and Dr Shaqireen for guiding me through basic laboratory technique when I first joined the group, Dr. Gan Shu Uin, Dr. Angela Moh and Ms Tan Teng Ee for assisting me in the generation of transfected and knock down cell lines, and Ms Lee Shu Ying from the confocal unit, NUHS, for providing the necessary facility for my confocal imaging. In addition, I would also like to show my appreciation to Ms Pang Wan Lu who worked closely with me in this Hodgkin lymphoma project. Last but not least, I would also like to express my pleasure to work with all the members from Herbert Schwarz' laboratory, especially Zulkarnain, Qianqiao, Liang Kai and Andy who gave me a lot of support both technically and morally. ii TABLE OF CONTENTS DECLARATION i ACKNOWLEDGEMENT ii TABLE OF CONTENTS iii ABSTRACT vii LIST OF TABLES ix LIST OF FIGURES x LIST OF ABBREVIATION xii 1. INTRODUCTION 1 1.1 Hodgkin lymphoma 2 1.1.1 Etiology and pathophysiology 3 1.1.2 Immunosuppressive microenvironment 6 1.1.3 Association of HL with members of tumor necrosis 8 factor receptor family 1.2 CD137 and CD137L 1.2.1 Expression and characteristic of CD137 and 12 CD137L 1.2.2 Targeting CD137 for immunotherapy 16 1.2.3 CD137 and CD137L in malignant diseases 18 1.3 Trogocytosis 19 1.4 Research objectives 22 iii 2.
    [Show full text]
  • (TRAIL) Death Receptor-4 and Promotes Apoptosis Resistance in Cholangiocarcinoma
    University of Nebraska Medical Center DigitalCommons@UNMC Journal Articles: Biochemistry & Molecular Biology Biochemistry & Molecular Biology 2-2012 miR-25 targets TNF-related apoptosis inducing ligand (TRAIL) death receptor-4 and promotes apoptosis resistance in cholangiocarcinoma. Nataliya Razumilava Mayo Clinic Steve F. Bronk Mayo Clinic Rory L. Smoot Mayo Clinic Christian D. Fingas Mayo Clinic Nathan W. Werneburg Mayo Clinic Follow this and additional works at: https://digitalcommons.unmc.edu/com_bio_articles See next page for additional authors Part of the Medical Biochemistry Commons, and the Medical Molecular Biology Commons Recommended Citation Razumilava, Nataliya; Bronk, Steve F.; Smoot, Rory L.; Fingas, Christian D.; Werneburg, Nathan W.; Roberts, Lewis R.; and Mott, Justin L., "miR-25 targets TNF-related apoptosis inducing ligand (TRAIL) death receptor-4 and promotes apoptosis resistance in cholangiocarcinoma." (2012). Journal Articles: Biochemistry & Molecular Biology. 19. https://digitalcommons.unmc.edu/com_bio_articles/19 This Article is brought to you for free and open access by the Biochemistry & Molecular Biology at DigitalCommons@UNMC. It has been accepted for inclusion in Journal Articles: Biochemistry & Molecular Biology by an authorized administrator of DigitalCommons@UNMC. For more information, please contact [email protected]. Authors Nataliya Razumilava, Steve F. Bronk, Rory L. Smoot, Christian D. Fingas, Nathan W. Werneburg, Lewis R. Roberts, and Justin L. Mott This article is available at DigitalCommons@UNMC: https://digitalcommons.unmc.edu/com_bio_articles/19 NIH Public Access Author Manuscript Hepatology . Author manuscript; available in PMC 2013 February 1. NIH-PA Author ManuscriptPublished NIH-PA Author Manuscript in final edited Author Manu NIH-PA form as: Hepatology . 2012 February ; 55(2): 465–475.
    [Show full text]
  • Biolegend.Com
    Mechanisms of Cell Death TRAIL (TNFSF10) TNF-α Death Receptor 4 (TNFRSF10A/TRAIL-R1) Death Receptor 5 Zombie Dyes (TNFRSF10B/TRAIL-R2) Propidium Iodide (PI) BAT1, TIM-4 TNF RI (TNFRSF1A) 7-Amino-Actinomycin (7-AAD) MER TNF RII (TNFRSF1B) FAS-L GAS6 (TNFSF6/CD178) TRAIL (TNFSF10) Apoptotic Cell Death Domain Zombie Dyes Phosphatidylserine K63 Ubiquitin NH2 Removal ICAM3? ROCK1 NH CD14 2 Eat-Me Signals FAS Death Inducing Cytoskeletal Rearrangement, (TNFRSF6/CD95) Signaling Complex (DISC) TRADD Cytoskeletal Rearrangement, TRADD Decoy Receptor 2 FADD (TNFRSF10D/TRAIL-R4) Actomysin Contraction Engulfment RIP1 TWEAK RIP1 oxLDL (TNFSF12) FADD CIAP1/2 K63 Ubiquitination Blebbing CD36 Death Receptor 3 TWEAK (TNFSF12) PI FADD (TNFRSF25, APO-3) 7-AAD TRAF1 FADD Procaspase 8,10 TRAF 3 Phagocyte FLIP PANX1 Macrophage Monocyte Neutrophil Dendritic Cell Fibroblast Mast Cell Procaspase 8,10 NF-kB TWEAK-R (TNFRSF12A/Fn14) Find-Me Signals Lysophosphocholine C Caspase 8,10 TRAF5 TRAF2 Sphingosine-1-Phosphate G2A? Nucleotides A Decoy TRAIL Receptor R1 (TNFRSF23) Bid Cell Survival ATP, UTP Decoy TRAIL Receptor R2 (TNFRSF22) Sphingosine-1 TRADD Phosphate Receptor Decoy Receptor 1 (TNFRSF10C/TRAIL-R3) Procaspase 3 Proliferation RIP1 G P2y2 t-Bid Bcl-2 T Chemotaxis, Caspase 3 Bcl-2-xL, MCL-1 ? ICAD RIP1 Engulfment Degradation Bax, Bak Oligomerization TRADD Death Receptor 6 Extracellular ATP Bacterial pore-forming toxins TRAIL (TNFSF10) ICAD (TNFRSF21) Monosodium urate crystals Cholesterol crystals Death Receptor DNA Fragmentation Cholera toxin B, Mitochondria
    [Show full text]
  • Targeting TRAIL Death Receptor 4 with Trivalent DR4 Atrimer Complexes
    Published OnlineFirst July 16, 2012; DOI: 10.1158/1535-7163.MCT-12-0366 Molecular Cancer Therapeutic Discovery Therapeutics Targeting TRAIL Death Receptor 4 with Trivalent DR4 Atrimer Complexes Joshua E. Allen1,2, Roger Ferrini3, David T. Dicker1, Glenda Batzer3, Elise Chen3, Daniela I. Oltean3, Bing Lin3, Mark W. Renshaw3, Anke Kretz-Rommel3, and Wafik S. El-Deiry1,2 Abstract TRAIL is a trimeric protein that potently induces apoptosis in cancer cells by binding to the trimeric death receptors (DR4 or DR5). Death receptors are attractive therapeutic targets through both the recombinant TRAIL ligand as well as receptor agonist monoclonal antibodies. Although efficacy of the ligand is hampered by its short half-life, agonistic antibodies have a much longer half-life and have shown some clinical efficacy as antitumor agents. However, the efficacy of these antibodies may be limited by their bivalent nature that does not optimally mimic the trimeric ligand. To overcome limitations of currently used death receptor-targeting agents, we engineered trimeric proteins called Atrimer complexes that selectively bind DR4 and potently induce apoptosis in a variety of cancer cells. Atrimer complexes are based on human tetranectin, a trimeric plasma protein of approximately 60 kDa. Loop regions within the tetranectin C-type lectin domains (CTLD) were randomized to create a large phage display library that was used to select DR4-binding complexes. A panel of unique and potent agonist DR4 Atrimer complexes with subnanomolar affinity to DR4 and no detectable binding to DR5 or the decoy receptors was identified. Mechanism of action studies with a selected Atrimer complex, 1G2, showed that Atrimer complexes induce caspase-dependent and DR4-specific apoptosis in cancer cells while sparing normal human fibroblasts and, importantly, hepatocytes.
    [Show full text]
  • Death Receptor 4 and Bladder Cancer Risk1
    [CANCER RESEARCH 63, 1157–1159, March 15, 2003] Advances in Brief Death Receptor 4 and Bladder Cancer Risk1 Aditi Hazra, Robert M. Chamberlain, H. Barton Grossman, Yong Zhu, Margaret R. Spitz, and Xifeng Wu2 Departments of Epidemiology [A. H., R. M. C., Y. Z., M. R. S., X. W.] and Urology [H. B. G.], The University of Texas M. D. Anderson Cancer Center, Houston, Texas 77030 Abstract proteins such as FADD and TRADD. The adaptor protein also con- tains a death effector domain that mediates a homotypic interaction Tumor necrosis factor-related apoptosis-inducing ligand stimulates the with initiator procaspases 8 or 10, which activates effector caspase 3, extrinsic apoptotic pathway by binding to death receptors 4 (DR4) and 5 cleaves poly(ADP-ribose) polymerase, and degrades the DNA. (DR5). In DR4 exon 4, a C3G polymorphism at amino acid 626 located immediately 3؅ to one of the main receptor ligand interface regions, results Caspase 3 is the executioner of the cell, responsible for the last phase in a threonine3arginine change. We found that the DR4 exon 4 G/G of the cell’s destiny, the deliberate disassembly of the cell into genotype was associated with an overall decreased risk of bladder cancer apoptotic bodies (10–12). confidence interval (CI), Recently, a C3G single nucleotide polymorphism was identified %95 ;0.58 ؍ (in Caucasians [odds ratio (OR 0.38–0.88]. This protective effect was more apparent in younger individ- in exon 4 of the DR4 gene. Fisher et al. (9) found the 626 C3G -CI, 0.20–0.87) than in older individuals polymorphism in the ectodomain of the DR4 gene by direct sequenc %95 ;0.42 ؍ uals (OR -CI, ing of genomic DNA from tumor and normal samples.
    [Show full text]
  • Theranostics Downregulation of Death Receptor 4 Is Tightly Associated With
    Theranostics 2021, Vol. 11, Issue 8 3964 Ivyspring International Publisher Theranostics 2021; 11(8): 3964-3980. doi: 10.7150/thno.54824 Research Paper Downregulation of death receptor 4 is tightly associated with positive response of EGFR mutant lung cancer to EGFR-targeted therapy and improved prognosis Shuo Zhang1, Zhen Chen1, Puyu Shi1, Songqing Fan2, Yong He3, Qiming Wang4, Yixiang Li1, Suresh S. Ramalingam1, Taofeek K. Owonikoko1 and Shi-Yong Sun1 1. Department of Hematology and Medical Oncology, Emory University School of Medicine and Winship Cancer Institute, Atlanta, Georgia, USA. 2. Department of Pathology, The Second Xiangya Hospital, Central South University, Changsha, Hunan, China. 3. Department of Respiratory Disease, Daping Hospital, Chongqing, China. 4. Department of Internal Medicine, The Affiliated Cancer Hospital of Zhengzhou University, Henan Cancer Hospital, Zhengzhou, Henan, China. Corresponding author: Shi-Yong Sun, Ph.D., Department of Hematology and Medical Oncology, Emory University School of Medicine and Winship Cancer Institute, 1365-C Clifton Road, C3088, Atlanta, GA 30322. Phone: (404) 778-2170; Fax: (404) 778-5520; Email: [email protected]. © The author(s). This is an open access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/). See http://ivyspring.com/terms for full terms and conditions. Received: 2020.10.21; Accepted: 2021.01.19; Published: 2021.02.15 Abstract Death receptor 4 (DR4), a cell surface receptor, mediates apoptosis or induces inflammatory cytokine secretion upon binding to its ligand depending on cell contexts. Its prognostic impact in lung cancer and connection between EGFR-targeted therapy and DR4 modulation has not been reported and thus was the focus of this study.
    [Show full text]
  • (Ciap-1) Degradation by Caspase 8 During TNF-Related Apoptosis-Inducing Ligand (TRAIL)-Induced Apoptosis
    University of Nebraska Medical Center DigitalCommons@UNMC Journal Articles: Biochemistry & Molecular Biology Biochemistry & Molecular Biology 1-2011 Cellular inhibitor of apoptosis 1 (cIAP-1) degradation by caspase 8 during TNF-related apoptosis-inducing ligand (TRAIL)-induced apoptosis. Maria Eugenia Guicciardi Mayo Clinic Justin L. Mott University of Nebraska Medical Center, [email protected] Steven F. Bronk Mayo Clinic Satoshi Kurita Mayo Clinic Christian D. Fingas Mayo Clinic Follow this and additional works at: https://digitalcommons.unmc.edu/com_bio_articles See next page for additional authors Part of the Medical Biochemistry Commons, and the Medical Molecular Biology Commons Recommended Citation Guicciardi, Maria Eugenia; Mott, Justin L.; Bronk, Steven F.; Kurita, Satoshi; Fingas, Christian D.; and Gores, Gregory J., "Cellular inhibitor of apoptosis 1 (cIAP-1) degradation by caspase 8 during TNF-related apoptosis-inducing ligand (TRAIL)-induced apoptosis." (2011). Journal Articles: Biochemistry & Molecular Biology. 23. https://digitalcommons.unmc.edu/com_bio_articles/23 This Article is brought to you for free and open access by the Biochemistry & Molecular Biology at DigitalCommons@UNMC. It has been accepted for inclusion in Journal Articles: Biochemistry & Molecular Biology by an authorized administrator of DigitalCommons@UNMC. For more information, please contact [email protected]. Authors Maria Eugenia Guicciardi, Justin L. Mott, Steven F. Bronk, Satoshi Kurita, Christian D. Fingas, and Gregory J. Gores This article is available at DigitalCommons@UNMC: https://digitalcommons.unmc.edu/com_bio_articles/23 NIH Public Access Author Manuscript Exp Cell Res . Author manuscript; available in PMC 2012 January 1. NIH-PA Author ManuscriptPublished NIH-PA Author Manuscript in final edited Author Manu NIH-PA form as: Exp Cell Res .
    [Show full text]
  • Activation of Nuclear Factor-KB Contributes to Induction of Death Receptors and Apoptosis by the Synthetic Retinoid CD437 in DU145 Human Prostate Cancer Cells
    Research Article Activation of Nuclear Factor-KB Contributes to Induction of Death Receptors and Apoptosis by the Synthetic Retinoid CD437 in DU145 Human Prostate Cancer Cells Fengshuo Jin,1 Xiangguo Liu,2 Zhongmei Zhou,2 Ping Yue,2 Reuben Lotan,3 Fadlo R. Khuri,2 Leland W.K. Chung,1 and Shi-Yong Sun2 Departments of 1Urology and 2Hematology and Oncology, Winship Cancer Institute, Emory University School of Medicine, Atlanta, Georgia and 3Department of Thoracic/Head and Neck Medical Oncology, M.D. Anderson Cancer Center, Houston, Texas Abstract of multiple antiapoptotic genes, such as Bcl-2 and Bcl-XL. However, n Activation of the transcription factor, nuclear factor-KB(NF-KB), increasing evidence suggests the opposite role of NF- B activation results in up-regulation of not only antiapoptotic genes but by up-regulating the expression of some proapoptotic genes during induction of apoptosis by certain stimuli (1, 2). One example is also proapoptotic genes, including death receptor 4 (DR4) and n death receptor 5 (DR5). Therefore, NF-KB activation either that NF- B activation induces the expression of both death suppresses or promotes apoptosis depending on the type of receptor 4 (DR4) and death receptor 5 (DR5) genes, leading to stimulus or cell context. We showed previously that the enhancement of tumor necrosis factor (TNF)–related apoptosis- inducing ligand (TRAIL)–induced apoptosis (3). Many studies have synthetic retinoid, 6-[3-(1-adamantyl)-4-hydroxyphenyl]-2- n naphthalene carboxylic acid (CD437), effectively induces shown that NF- B activation in human prostate cancer represents apoptosis particularly in androgen-independent prostate a survival pathway leading to resistance to apoptosis, whereas inhibition of NF-nB by either small molecules or dominant-negative carcinoma cells.
    [Show full text]
  • Cell Structure & Function
    Cell Structure & Function Antibodies and Reagents BioLegend is ISO 13485:2016 Certified Toll-Free Tel: (US & Canada): 1.877.BIOLEGEND (246.5343) Tel: 858.768.5800 biolegend.com 02-0012-03 World-Class Quality | Superior Customer Support | Outstanding Value Table of Contents Introduction ....................................................................................................................................................................................3 Cell Biology Antibody Validation .............................................................................................................................................4 Cell Structure/ Organelles ..........................................................................................................................................................8 Cell Development and Differentiation ................................................................................................................................10 Growth Factors and Receptors ...............................................................................................................................................12 Cell Proliferation, Growth, and Viability...............................................................................................................................14 Cell Cycle ........................................................................................................................................................................................16 Cell Signaling ................................................................................................................................................................................18
    [Show full text]
  • Death Receptor 5, a New Member of the TNFR Family, and DR4 Induce FADD-Dependent Apoptosis and Activate the NF-␬B Pathway
    View metadata, citation and similar papers at core.ac.uk brought to you by CORE provided by Elsevier - Publisher Connector Immunity, Vol. 7, 821±830, December, 1997, Copyright 1997 by Cell Press Death Receptor 5, a New Member of the TNFR Family, and DR4 Induce FADD-Dependent Apoptosis and Activate the NF-kB Pathway Preet M. Chaudhary, Michael Eby, a C-terminal death domain through which it binds to the Alan Jasmin, Angela Bookwalter, death domain of Fas/Apo-1 (Boldin et al., 1995; Chinnai- Jessica Murray, and Leroy Hood* yan et al., 1995). Despite its sequence homology to the Department of Molecular Biotechnology similar domains present in the death domain±containing University of Washington receptors, the death domain of FADD cannot induce Seattle, Washington 98195 apoptosis when overexpressed in mammalian cells and, in fact, can block the apoptosis mediated by Fas and TNFR1 in a dominant-negative fashion (Chinnaiyan et Summary al., 1995; Hsu et al., 1996b). FADD possesses another domain called the death effector domain at its N termi- Death receptor4 (DR4) is a recently described receptor nus, which can induce apoptosis when overexpressed for the cytotoxic ligand TRAIL that reportedly uses a in mammalian cells (Chinnaiyan et al., 1995; Hsu et al., FADD-independent pathway to induce apoptosis and 1996b). Through its death effector domain, FADD binds does not activate the NF-kB pathway. We have iso- to the proapoptotic apical caspase, Caspase 8 (also lated a new member of the tumor necrosis factor re- called FLICE, MACH, or Mch5) (Boldin et al., 1996; Fer- ceptor (TNFR) family, designated DR5, which bears a nandes-Alnemri et al., 1996; Muzio et al., 1996).
    [Show full text]